Esophageal Cancer

  • Robert L Eil
  • F. E. M. Voncken
  • J. Torres-Roca
  • Charles R ThomasJr.
Part of the Medical Radiology book series (MEDRAD)


Despite ongoing advances, the vast majority of those afflicted with esophageal cancer go on to die of their disease. While some respond notably to chemoradiotherapy, others-with seemingly similar disease characteristics based on existing clinical assays-have a limited or absent response. The current climate is suitable for the development of predictive tools and novel methods of evaluation to aid in individualised patient treatment planning. In the preoperative setting our clinical staging and varied imaging modalities, although imperfect are used to determine which patients will likely receive from chemoradiotherapy. No permutation of the data currently available can predict, with a satisfactory accuracy, whether an individual patient will have a substantial response to neoadjuvant treatment with minimal morbidity. Potentially, the addition of molecular assays in tandem with standardization of radiologic data will allow the development of increasingly powerful tools to predict the likelihood of response to treatment without complication for an individual patient.


Esophageal Cancer Standard Uptake Value Radiation Pneumonitis Esophageal Cancer Patient Concordance Index 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Ahn SJ, Kahn D, Zhou S et al (2005) Dosimetric and clinical predictors for radiation-induced esophageal injury. Int J Radiat Oncol Biol Phys 61(2):335–347PubMedCrossRefGoogle Scholar
  2. Ajani JA, Winter K, Komaki R et al (2008) Phase II randomized trial of two nonoperative regimens of induction chemotherapy followed by chemoradiation in patients with localized carcinoma of the esophagus: RTOG 0113. J Clin Oncol 26(28):4551–4556PubMedCentralPubMedCrossRefGoogle Scholar
  3. Ajani JA, Correa AM, Hofstetter WL et al (2012) Clinical parameters model for predicting pathologic complete response following preoperative chemoradiation in patients with esophageal cancer. Ann Oncol 23(10):2638–2642PubMedCentralPubMedCrossRefGoogle Scholar
  4. Aoyagi T, Shuto K, Okazumi S, Shimada H, Kazama T, Matsubara H (2011) Apparent diffusion coefficient values measured by diffusion-weighted imaging predict chemoradiotherapeutic effect for advanced esophageal cancer. Dig Surg 28(4):252–257PubMedCrossRefGoogle Scholar
  5. Asakura H, Hashimoto T, Zenda S et al (2010) Analysis of dose-volume histogram parameters for radiation pneumonitis after definitive concurrent chemoradiotherapy for esophageal cancer. Radiother Oncol 95(2):240–244PubMedCrossRefGoogle Scholar
  6. Berger AC, Farma J, Scott WJ et al (2005) Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. J Clin Oncol 23(19):4330–4337PubMedCrossRefGoogle Scholar
  7. Botet JF, Lightdale CJ, Zauber AG, Gerdes H, Urmacher C, Brennan MF (1991) Preoperative staging of esophageal cancer: comparison of endoscopic US and dynamic CT. Radiology 181(2):419–425PubMedGoogle Scholar
  8. Bowrey DJ, Clark GW, Roberts SA et al (1999) Serial endoscopic ultrasound in the assessment of response to chemoradiotherapy for carcinoma of the esophagus. J Gastrointest Surg 3(5):462–467PubMedCrossRefGoogle Scholar
  9. Brucher BL, Becker K, Lordick F, Fink U, Sarbia M, Stein H, Busch R, Zimmerman F, Molls M, Hofler H, Siewart JR (2006) The clinical impact of histopathologic response assessment by residual tumor cell quantification in esopahgeal squamous cell carcinomas. Cancer 106(10):2119–2126PubMedCrossRefGoogle Scholar
  10. Bruzzi JF, Swisher SG, Truong MT et al (2007) Detection of interval distant metastases: clinical utility of integrated CT-PET imaging in patients with esophageal carcinoma after neoadjuvant therapy. Cancer 109(1):125–134PubMedCrossRefGoogle Scholar
  11. Burmeister BH, Smithers BM, Gebski V et al (2005) Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncol 6(9):659–668PubMedCrossRefGoogle Scholar
  12. Chak A, Canto MI, Cooper GS et al (2000) Endosonographic assessment of multimodality therapy predicts survival of esophageal carcinoma patients. Cancer 88(8):1788–1795PubMedCrossRefGoogle Scholar
  13. Chang EY (2009) Esophageal cancer: principles and practice. Demos Medical Publisher, New YorkGoogle Scholar
  14. Chang EY, Li X, Jerosch-Herold M et al (2008) The evaluation of esophageal adenocarcinoma using dynamic contrast-enhanced magnetic resonance imaging. J Gastrointest Surg 12(1):166–175PubMedCrossRefGoogle Scholar
  15. Chirieac LR, Swisher SG, Ajani JA, Komaki RR, Correa AM, Morris JS, Roth JA, Rashid A, Hamilton SR, Wu TT (2005) Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation. Cancer 103:1347–1355PubMedCrossRefGoogle Scholar
  16. Cooper JS, Guo MD, Herskovic A et al (1999) Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA 281(17):1623–1627PubMedCrossRefGoogle Scholar
  17. Dalton WS, Friend SH (2006) Cancer biomarkers—An invitation to the table. Science 312:1165–1168PubMedCrossRefGoogle Scholar
  18. David IH (2008) Esophageal cancer chemotherapy: recent advances. Gastrointest Cancer Res 2:85–92Google Scholar
  19. Dikken JL, Coit DG, Klimstra DS et al (2012) Prospective impact of tumor grade assessment in biopsies on tumor stage and prognostic grouping in gastroesophageal adenocarcinoma: relevance of the seventh edition American joint committee on cancer staging manual revision. Cancer 118(2):349–357PubMedCrossRefGoogle Scholar
  20. Donahue JM, Nichols FC, Li Z, Schomas DA, Allen MS, Cassivi SD, Jatoi A, Miller RC, Wigle DA, Shen R, Deschamps C (2009a) Complete pathologic response after neoadjuvant chemoradiotherapy for esophageal cancer is associated with enchanced survival. Ann Thoracic Surg 87(2):392–399CrossRefGoogle Scholar
  21. Donahue JM, Nichols FC, Li Z, Schomas DA, Allen MS, Cassivi SD, Jatoi A, Miller RC, Wigle DA, Shen R, Deschamps C (2009b) Complete pathologic response after neoadjuvant chemoradiotherapy for esophageal cancer is associated with enchanced survival. Ann Thoracic Surg 87(2):392–399CrossRefGoogle Scholar
  22. Eil R, Diggs BS, Wang SJ, Dolan J, Hunter JG, Thomas CR (2013) Nomogram for predicting the benefit of neoadjuvant chemoradiotherapy for esophageal cancer – A SEER – medicare analysis. Presented: ASCO Annual Meeting, 31 May to 4 June 2013, ChicagoGoogle Scholar
  23. Eschrich S, Zhang H et al (2009a) Systems biology modeling of the radiation sensitivty network: a biomarker discovery platform. Int J Radiat Oncol Biol Phys 75(2):497–505PubMedCentralPubMedCrossRefGoogle Scholar
  24. Eschrich S, Pramana J et al (2009b) A gene expression model of intrinsic tumor radiosensitivity: prediction of response and prognosis after chemoradiation. Int J Radiat Oncol Biol Phys 75(2):489–496PubMedCentralPubMedCrossRefGoogle Scholar
  25. Fockens P, Van den Brande JH, van Dullemen HM, van Lanschot JJ, Tytgat GN (1996) Endosonographic T-staging of esophageal carcinoma: a learning curve. Gastrointest Endosc 44(1):58–62PubMedCrossRefGoogle Scholar
  26. Gaur P, Sepesi B, Hofstetter WL, Correa AM, Bhutani MS, Vaporciyan AA, Watson TJ, Swisher SG (2010) A clinical nomogram predicting pathologic lymph node involvement in esophageal cancer patients. Ann Surg 252(4):611–617PubMedGoogle Scholar
  27. Gayed IW, Liu HH, Yusuf SW et al (2006) The prevalence of myocardial ischemia after concurrent chemoradiation therapy as detected by gated myocardial perfusion imaging in patients with esophageal cancer. J Nucl Med 47(11):1756–1762PubMedGoogle Scholar
  28. Giovannini M, Seitz JF, Thomas P et al (1997) Endoscopic ultrasonography for assessment of the response to combined radiation therapy and chemotherapy in patients with esophageal cancer. Endoscopy 29(1):4–9PubMedCrossRefGoogle Scholar
  29. Griffith JF, Chan AC, Chow LT et al (1999) Assessing chemotherapy response of squamous cell oesophageal carcinoma with spiral CT. Br J Radiol 72(859):678–684PubMedGoogle Scholar
  30. Hashimoto T, Asakura H, Zenda S et al (2008) Cardiac toxicities after concurrent chemoradiotherapy for esophageal cancer- dose volume histogram. Int J Radiat Oncol Biol Phys 72(1):S130CrossRefGoogle Scholar
  31. Heath EI, Burtness BA, Heitmiller RF et al (2000) Phase II evaluation of preoperative chemoradiation and postoperative adjuvant chemotherapy for squamous cell and adenocarcinoma of the esophagus. J Clin Oncol 18(4):868–876PubMedGoogle Scholar
  32. Hirata N, Kawamoto K, Ueyama T, Masuda K, Utsunomiya T, Kuwano H (1997) Using endosonography to assess the effects of neoadjuvant therapy in patients with advanced esophageal cancer. AJR Am J Roentgenol 169(2):485–491PubMedCrossRefGoogle Scholar
  33. Holmes RS, Vaughan TL (2007) Epidemiology and pathogenesis of esophageal cancer. Semin Radiat Oncol 17(1):2–9PubMedCrossRefGoogle Scholar
  34. Hsu FM, Lee YC, Lee JM et al (2009) Association of clinical and dosimetric factors with postoperative pulmonary complications in esophageal cancer patients receiving intensity-modulated radiation therapy and concurrent chemotherapy followed by thoracic esophagectomy. Ann Surg Oncol 16(6):1669–1677PubMedCrossRefGoogle Scholar
  35. Jamil LH, Gill KR, Wallace MB (2008) Staging and restaging of advanced esophageal cancer. Curr Opin Gastroenterol 24(4):530–534PubMedCrossRefGoogle Scholar
  36. Jasonos A, Schrag D, Raj G, Panageas K (2008) How to build and interpret a nomogram for cancer prognosis. J Clin Oncol 26:1364–1370CrossRefGoogle Scholar
  37. Jones DR, Parker LA Jr, Detterbeck FC, Egan TM (1999) Inadequacy of computed tomography in assessing patients with esophageal carcinoma after induction chemoradiotherapy. Cancer 85(5):1026–1032PubMedCrossRefGoogle Scholar
  38. Kalha I, Kaw M, Fukami N, Patel M, Singh S, Gagneja H, Cohen D, Morris J (2004) The accuracy of endoscopic ultrasound for restaging esophageal carcinoma after chemoradiation therapy. Cancer 101(5):940–947PubMedCrossRefGoogle Scholar
  39. Katsoulis IE, Wong WL, Mattheou AK, Damani N, Chambers J, Livingstone JI (2007) Fluorine-18 fluorodeoxyglucose positron emission tomography in the preoperative staging of thoracic oesophageal and gastro-oesophageal junction cancer: a prospective study. Int J Surg 5(6):399–403PubMedCrossRefGoogle Scholar
  40. Konski A, Li T, Christensen M et al (2012) Symptomatic cardiac toxicity is predicted by dosimetric and patient factors rather than changes in 18F-FDG PET determination of myocardial activity after chemoradiotherapy for esophageal cancer. Radiother Oncol 104(1):72–77PubMedCentralPubMedCrossRefGoogle Scholar
  41. Kwa SL, Lebesque JV, Theuws JC et al (1998) Radiation pneumonitis as a function of mean lung dose: an analysis of pooled data of 540 patients. Int J Radiat Oncol Biol Phys 42(1):1–9PubMedCrossRefGoogle Scholar
  42. Lin SH, Wang L, Myles B et al (2012) Propensity score-based comparison of long-term outcomes with 3-dimensional conformal radiotherapy vs intensity-modulated radiotherapy for esophageal cancer. Int J Radiat Oncol Biol Phys 84(5):1078–1085PubMedCentralPubMedCrossRefGoogle Scholar
  43. Lowe VJ, Booya F, Fletcher JG et al (2005) Comparison of positron emission tomography, computed tomography, and endoscopic ultrasound in the initial staging of patients with esophageal cancer. Mol Imaging Biol 7(6):422–430PubMedCrossRefGoogle Scholar
  44. Meluch AA, Greco FA, Gray JR et al (2003) Preoperative therapy with concurrent paclitaxel/carboplatin/infusional 5-FU and radiation therapy in locoregional esophageal cancer: final results of a Minnie Pearl cancer research network phase II trial. Cancer J 9(4):251–260PubMedCrossRefGoogle Scholar
  45. Milano MT, Constine LS, Okunieff P (2007) Normal tissue tolerance dose metrics for radiation therapy of major organs. Semin Radiat Oncol 17(2):131–140PubMedCrossRefGoogle Scholar
  46. Minsky B, Pajak T, Ginsberg R, Pisansky T, Martenson J, Komaki R, Okawara G, Rosenthal S, Kelsen D (2002) INT 0123 (radiation therapy oncology group 94–05) phase III trial of combined mortality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. JCO 20:1167–1174CrossRefGoogle Scholar
  47. Morota M, Gomi K, Kozuka T et al (2009) Late toxicity after definitive concurrent chemoradiotherapy for thoracic esophageal carcinoma. Int J Radiat Oncol Biol Phys 75(1):122–128PubMedCrossRefGoogle Scholar
  48. Nomura M, Kodaira T, Furutani K, Tachibana H, Tomita N, Goto Y (2012) Predictive factors for radiation pneumonitis in oesophageal cancer patients treated with chemoradiotherapy without prophylactic nodal irradiation. Br J Radiol 85(1014):813–818PubMedCentralPubMedCrossRefGoogle Scholar
  49. Oberholzer K, Pohlmann A, Schreiber W et al (2008) Assessment of tumor microcirculation with dynamic contrast-enhanced MRI in patients with esophageal cancer: initial experience. J Magn Reson Imaging 27(6):1296–1301PubMedCrossRefGoogle Scholar
  50. Omloo JM, van Heijl M, Hoekstra OS, van Berge Henegouwen MI, van Lanschot JJ, Sloof GW (2011) FDG-PET parameters as prognostic factor in esophageal cancer patients: a review. Ann Surg Oncol 18(12):3338–3352PubMedCentralPubMedCrossRefGoogle Scholar
  51. Palma DA, Senan S, Tsujino K, et al (2012) Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data meta-analysis. Int J Radiat Oncol Biol Phys 85(2):444–450Google Scholar
  52. Reid TD, Chan DS, Roberts SA, Crosby TD, Williams GT, Lewis WG (2012) Prognostic significance of circumferential resection margin involvement following oesophagectomy for cancer and the predictive role of endoluminal ultrasonography. Br J Cancer 107(12):1925–1931PubMedCentralPubMedCrossRefGoogle Scholar
  53. Reynolds JV, McLaughlin R, Moore J, Rowley S, Ravi N, Byrne PJ (2006) Prospective evaluation of quality of life in patients with localized oesophageal cancer treated by multimodality therapy or surgery alone. Br J Surg 93(9):1084–1090PubMedCrossRefGoogle Scholar
  54. Ribeiro A, Franceschi D, Parra J et al (2006) Endoscopic ultrasound restaging after neoadjuvant chemotherapy in esophageal cancer. Am J Gastroenterol 101:1216–1221PubMedCrossRefGoogle Scholar
  55. Rice TW, Blackstone EH, Rusch VW (2010) 7th edition of the AJCC cancer staging manual: esophagus and esophagogastric junction. Ann Surg Oncol 17(7):1721–1724PubMedCrossRefGoogle Scholar
  56. Riddell AM, Allum WH, Thompson JN, Wotherspoon AC, Richardson C, Brown G (2007) The appearances of oesophageal carcinoma demonstrated on high-resolution, T2-weighted MRI, with histopathological correlation. Eur Radiol 17(2):391–399PubMedCrossRefGoogle Scholar
  57. Rizk NP, Seshan VE, Bains MS et al (2007a) Prognostic factors after combined modality treatment of squamous cell carcinoma of the esophagus. J Thorac Oncol 2(12):1117–1123PubMedCrossRefGoogle Scholar
  58. Rizk NP, Venkatraman E, Bains MS et al (2007b) American joint committee on cancer staging system does not accurately predict survival in patients receiving multimodality therapy for esophageal adenocarcinoma. J Clin Oncol 25(5):507–512PubMedCrossRefGoogle Scholar
  59. Rose J, Rodrigues G, Yaremko B, Lock M, D’Souza D (2009) Systematic review of dose-volume parameters in the prediction of esophagitis in thoracic radiotherapy. Radiother Oncol 91(3):282–287PubMedCrossRefGoogle Scholar
  60. Sakurada A, Takahara T, Kwee TC et al (2009) Diagnostic performance of diffusion-weighted magnetic resonance imaging in esophageal cancer. Eur Radiol 19(6):1461–1469PubMedCrossRefGoogle Scholar
  61. Sarkaria IS, Rizk NP, Bains MS et al (2009) Post-treatment endoscopic biopsy is a poor-predictor of pathologic response in patients undergoing chemoradiation therapy for esophageal cancer. Ann Surg 249(5):764–767PubMedCrossRefGoogle Scholar
  62. Siegel R, DeSantis C, Virgo K et al (2012) Cancer treatment and survivorship statistics. CA Cancer J Clin 62(4):220–241PubMedCrossRefGoogle Scholar
  63. Siewert JR, Stein HJ (1998) Classification of adenocarcinoma of the oesophagogastric junction. Br J Surg 85(11):1457–1459PubMedCrossRefGoogle Scholar
  64. Situ D, Wei W, Lin P, et al (2012) Do tumor grade and location affect survival in esophageal squamous cell carcinoma? Survival analysis of 302 cases of pT3N0M0 esophageal squamous cell carcinoma. Ann Surg Oncol 20:580–585Google Scholar
  65. Sloof GW (2006) Response monitoring of neoadjuvant therapy using CT, EUS, and FDG-PET. Best Pract Res Clin Gastroenterol 20(5):941–957PubMedCrossRefGoogle Scholar
  66. Stahl A, Ott K, Weber WA et al (2003) FDG PET imaging of locally advanced gastric carcinomas: correlation with endoscopic and histopathological findings. Eur J Nucl Med Mol Imaging 30(2):288–295PubMedCrossRefGoogle Scholar
  67. Streyerberg EW, Neville BA, Koppert LB, Lemmens VE, Tilanus HW, Coebergh JW, Weeks JC, Earle CC (2008) Surgical mortality in patients with esophageal cancer: development and validation of a simple risk score. JCO 24:4277–4283CrossRefGoogle Scholar
  68. Suzuki A, Xiao L, Hayashi Y, Blum M, Welsh J, Lin S, Lee J, Bhutani M, Weston B, Maru D, Rice D, Swisher S, Hostetter W, Erasmus J, Ajani JA (2012) Nomograms for prognostication of outcome in patients with esophageal and gastroesophageal carcinoma underoing definitive chemoradiotherapy. Oncology 82:108–113PubMedCrossRefGoogle Scholar
  69. Swisher SG, Maish M, Erasmus JJ, et al (2004) Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer. Ann Thorac Surg 78(4):1152–1160; discussion 1152–1160Google Scholar
  70. Swisher S, Hofstetter W, Wu T, Correa AM, Ajani JA, Komaki RR, Chirieac L, Hunt K, Liao Z, Phan A, Rice D, Vaporciyan AA, Walsh G, Roth J (2005) Proposed revision of the esophgeal cancer staging sytem to accommodate pathologic following preoperative chemoradiation. Ann Surg 241(5):810–820PubMedCentralPubMedCrossRefGoogle Scholar
  71. Talsma K, van Hagen P, Grotenhuis BA et al (2012) Comparison of the 6th and 7th editions of the UICC-AJCC TNM classification for esophageal cancer. Ann Surg Oncol 19(7):2142–2148PubMedCentralPubMedCrossRefGoogle Scholar
  72. Thosani N, Singh H, Kapadia A et al (2012) Diagnostic accuracy of EUS in differentiating mucosal versus submucosal invasion of superficial esophageal cancers: a systematic review and meta-analysis. Gastrointest Endosc 75(2):242–253PubMedCrossRefGoogle Scholar
  73. Thrift AP, Nagle CM, Fahey PP et al (2012) The influence of prediagnostic demographic and lifestyle factors on esophageal squamous cell carcinoma survival. Int J Cancer 131(5):E759–E768PubMedCrossRefGoogle Scholar
  74. Trotti A, Colevas AD, Setser A et al (2003) CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13(3):176–181PubMedCrossRefGoogle Scholar
  75. Tucker SL, Liu HH, Wang S et al (2006) Dose-volume modeling of the risk of postoperative pulmonary complications among esophageal cancer patients treated with concurrent chemoradiotherapy followed by surgery. Int J Radiat Oncol Biol Phys 66(3):754–761PubMedCrossRefGoogle Scholar
  76. Union Internationale Contre le Cancer (2002) TNM classification of malignant tumours, 6th edn. Wiley-Liss, New YorkGoogle Scholar
  77. Urba SG, Orringer MB, Turrisi A, Iannettoni M, Forastiere A, Strawderman M (2001) Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol 19(2):305–313PubMedGoogle Scholar
  78. Urba SG, Orringer MB, Ianettonni M, Hayman JA, Satoru H (2003) Concurrent cisplatin, paclitaxel, and radiotherapy as preoperative treatment for patients with locoregional esophageal carcinoma. Cancer 98(10):2177–2183PubMedCrossRefGoogle Scholar
  79. Van Benthuysen L, Hales L, Podgorsak MB (2011) Volumetric modulated arc therapy vs. IMRT for the treatment of distal esophageal cancer. Med Dosim 36(4):404–409Google Scholar
  80. van Hagen P, Hulshof MC, van Lanschot JJ et al (2012) Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 366(22):2074–2084PubMedCrossRefGoogle Scholar
  81. van Meerten E, Muller K, Tilanus HW et al (2006) Neoadjuvant concurrent chemoradiation with weekly paclitaxel and carboplatin for patients with oesophageal cancer: a phase II study. Br J Cancer 94(10):1389–1394PubMedCentralPubMedCrossRefGoogle Scholar
  82. van Meerten E, van der Gaast A, Looman CW, Tilanus HW, Muller K, Essink-Bot ML (2008) Quality of life during neoadjuvant treatment and after surgery for resectable esophageal carcinoma. Int J Radiat Oncol Biol Phys 71(1):160–166PubMedCrossRefGoogle Scholar
  83. van Vliet EP, Heijenbrok-Kal MH, Hunink MG, Kuipers EJ, Siersema PD (2008) Staging investigations for oesophageal cancer: a meta-analysis. Br J Cancer 98(3):547–557PubMedCentralPubMedCrossRefGoogle Scholar
  84. Vivekanandan N, Sriram P, Kumar SA, Bhuvaneswari N, Saranya K (2012) Volumetric modulated arc radiotherapy for esophageal cancer. Med Dosim Spring 37(1):108–113CrossRefGoogle Scholar
  85. Vogelius IR, Bentzen SM (2012) A literature-based meta-analysis of clinical risk factors for development of radiation induced pneumonitis. Acta Oncol 51(8):975–983PubMedCentralPubMedCrossRefGoogle Scholar
  86. Voncken FE, Jiang H, Kim J, et al (2012) Degree of tumor shrinkage following neoadjuvant chemoradiotherapy: a potential predictor for complete pathological response in esophageal cancer? Dis Esophagus. doi: 10.1111/j.1442-2050.2012.01445.xGoogle Scholar
  87. Wagner TD, Javie M, Yang G (2009) Esophageal cancer: principles and practice. Demos Medical Publisher, New YorkGoogle Scholar
  88. Wang SL, Liao Z, Vaporciyan AA et al (2006) Investigation of clinical and dosimetric factors associated with postoperative pulmonary complications in esophageal cancer patients treated with concurrent chemoradiotherapy followed by surgery. Int J Radiat Oncol Biol Phys 64(3):692–699PubMedCrossRefGoogle Scholar
  89. Wang S, Liao Z, Wei X et al (2008) Association between systemic chemotherapy before chemoradiation and increased risk of treatment-related pneumonitis in esophageal cancer patients treated with definitive chemoradiotherapy. J Thorac Oncol 3(3):277–282PubMedCrossRefGoogle Scholar
  90. Watanabe T, Komuro Y, Kiyomatsu T, Kanazawa T, Kazama Y, Tanaka J, Tanaka T, Yamamoto Y, Shirane M, Muto T, Nagawa H (2006) Prediction of sensitivity of rectal cancer cells in response to preoperative radio- therapy by DNA microarray analysis of gene expression profiles. Cancer Res 66:3370–3374PubMedCrossRefGoogle Scholar
  91. Wei X, Liu HH, Tucker SL et al (2008) Risk factors for pericardial effusion in inoperable esophageal cancer patients treated with definitive chemoradiation therapy. Int J Radiat Oncol Biol Phys 70(3):707–714PubMedCrossRefGoogle Scholar
  92. Weichselbaum RR, Ishwaranc H et al (2008) An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer. PNAS 105:18490–18495PubMedCentralPubMedCrossRefGoogle Scholar
  93. Westerterp M, van Westreenen HL, Reitsma JB et al (2005) Esophageal cancer: CT, endoscopic US, and FDG PET for assessment of response to neoadjuvant therapy–systematic review. Radiology 236(3):841–851PubMedCrossRefGoogle Scholar
  94. Wong WL, Chambers RJ (2008) Role of PET/PET CT in the staging and restaging of thoracic oesophageal cancer and gastro-oesophageal cancer: a literature review. Abdom Imaging 33(2):183–190PubMedCrossRefGoogle Scholar
  95. Wu LF, Wang BZ, Feng JL et al (2003) Preoperative TN staging of esophageal cancer: comparison of miniprobe ultrasonography, spiral CT and MRI. World J Gastroenterol 9(2):219–224PubMedGoogle Scholar
  96. Yin L, Wu H, Gong J et al (2012) Volumetric-modulated arc therapy vs. c-IMRT in esophageal cancer: a treatment planning comparison. World J Gastroenterol 18(37):5266–5275PubMedCentralPubMedGoogle Scholar
  97. Zuccaro G Jr, Rice TW, Goldblum J et al (1999) Endoscopic ultrasound cannot determine suitability for esophagectomy after aggressive chemoradiotherapy for esophageal cancer. Am J Gastroenterol 94(4):906–912PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • Robert L Eil
    • 1
  • F. E. M. Voncken
    • 2
  • J. Torres-Roca
    • 3
  • Charles R ThomasJr.
    • 4
  1. 1.Department of SurgeryOregon Health & Science UniversityPortlandUSA
  2. 2.Department of RadiotherapyThe Netherlands Cancer Institute-Antoni van Leeuwenhoek HospitalAmsterdamNetherlands
  3. 3.Department of Radiation OncologyH Lee Moffitt Cancer CenterTampaUSA
  4. 4.Department Radiation MedicineOregon Health & Science UniversityPortlandUSA

Personalised recommendations